Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03827668 · ClinicalTrials.gov registry record · Phase 1

A Drug-drug Interaction Study Between PF-06650833 AND PF-06651600 Following Multiple Doses IN Healthy Participants

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT03827668: Completed Phase 1 study, sponsored by Pfizer.

NCT03827668 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03827668, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.

Primary Outcome

Maximum observed concentration (Cmax) derived from plasma

Interventions

  • DRUG PF-06650833 alone
  • DRUG PF-06651600 alone
  • DRUG PF-06650833 together with PF-06651600

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-02-07
Est. Completion 2019-04-29
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT03827668 record still lists

NCT03827668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 3 interventions - of which PF-06650833 alone is the first listed.

NCT03827668 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03827668 about?

NCT03827668 is a clinical study titled "A Drug-drug Interaction Study Between PF-06650833 AND PF-06651600 Following Multiple Doses IN Healthy Participants". The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.

What is the current status of trial NCT03827668?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-02-07. Estimated completion is 2019-04-29.

What interventions are being tested in trial NCT03827668?

The interventions under investigation include: PF-06650833 alone (DRUG), PF-06651600 alone (DRUG), PF-06650833 together with PF-06651600 (DRUG).

Who is sponsoring clinical trial NCT03827668?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03827668's enrollment target sits among peer trials

15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03827668, the US trial registry maintained by the National Library of Medicine. NCT03827668 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.